Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MYL-1401A
- Development stage
- Phase 3
- Lead developer
- Biocon
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
**MYL-1401A** is a recombinant human IgG1 monoclonal antibody biosimilar to adalimumab (Humira), developed by Biocon and originally partnered with Mylan (now part of Viatris). It functions as a tumor necrosis factor alpha (TNFα) inhibitor, binding to TNFα to prevent activation of TNF receptors, thereby downregulating inflammatory responses in autoimmune conditions. Primary evaluations have focused on rheumatoid arthritis (Phase III) and plaque psoriasis (Phase III, with efficacy, safety, and pharmacokinetics data released), administered subcutaneously as an injectable therapy.[1][3][5][14]
- Other names
- adalimumab biosimilar
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on MYL-1401A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MYL-1401A.